Resolution of the circulating pathogenic phenotype of alpha-1 antitrypsin deficiency following liver transplantation

Alpha-1 antitrypsin (AAT) is a protease inhibitor, normally found at a high concentration in monomeric form in the circulation from where it protects the lung tissue from proteolytic damage. Pathogenic variants of AAT self-assemble into flexible polymer chains that undergo toxic accumulation in the liver, underlying the development of liver disease; the corresponding deficiency in the circulation results in susceptibility to emphysema. AAT polymers formed by these variants are also detectable in the plasma; this study evaluated the dynamics of circulating monomeric and polymeric AAT after correction of the deficiency state with liver transplantation in four individuals homozygous for the Z deficiency allele (Glu342Lys). The resolution of the pathological circulating AAT phenotype was characterised by analysis of blood samples taken pre- and post-liver transplant using a panel of conformer-specific monoclonal antibodies and a novel ELISA with enhanced sensitivity for AAT polymers. Circulating wild-type M AAT, produced by the allograft liver, increased with a half-time of 7-39 h, attaining a putative 'protective' threshold level 4-55 h post-transplant. Pre-transplant circulating polymer levels ranged from 5 to 26 μg/ml and declined post-surgery with a half-time of 2-9 h, with levels comparable to those of wild-type M AAT plasma when measured >200 days post-transplant. The glycosylation profile of liver- and plasma-derived polymers and their progressive disappearance from circulation is consistent with their origin in, and canonical secretion from, the liver. To our knowledge this is the first post-transplant evaluation of the hybrid conformational profile of endogenous and donor tissue-derived AAT.

Authors

Institutions

Publication Details

Journal
Bioscience Reports
Published
2026-11-19
DOI
https://doi.org/10.1042/bsr20260597
Primary Topic
Protease and Inhibitor Mechanisms
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Resolution of the circulating pathogenic phenotype of alpha-1 antitrypsin deficiency following liver transplantation

Ibrahim Aldobiyan, John Robert Hurst, David A. Lomas, James A. Irving et al.
2 links
Bioscience Reports
Protease and Inhibitor Mechanisms
article

Resolution of the circulating pathogenic phenotype of alpha-1 antitrypsin deficiency following liver transplantation

Ibrahim Aldobiyan, John Robert Hurst, David A. Lomas, James A. Irving, Riccardo Ronzoni, Elena Miranda, Nina Heyer‐Chauhan, Aileen Marshall
article en

Abstract

Alpha-1 antitrypsin (AAT) is a protease inhibitor, normally found at a high concentration in monomeric form in the circulation from where it protects the lung tissue from proteolytic damage. Pathogenic variants of AAT self-assemble into flexible polymer chains that undergo toxic accumulation in the liver, underlying the development of liver disease; the corresponding deficiency in the circulation results in susceptibility to emphysema. AAT polymers formed by these variants are also detectable in the plasma; this study evaluated the dynamics of circulating monomeric and polymeric AAT after correction of the deficiency state with liver transplantation in four individuals homozygous for the Z deficiency allele (Glu342Lys). The resolution of the pathological circulating AAT phenotype was characterised by analysis of blood samples taken pre- and post-liver transplant using a panel of conformer-specific monoclonal antibodies and a novel ELISA with enhanced sensitivity for AAT polymers. Circulating wild-type M AAT, produced by the allograft liver, increased with a half-time of 7-39 h, attaining a putative 'protective' threshold level 4-55 h post-transplant. Pre-transplant circulating polymer levels ranged from 5 to 26 μg/ml and declined post-surgery with a half-time of 2-9 h, with levels comparable to those of wild-type M AAT plasma when measured >200 days post-transplant. The glycosylation profile of liver- and plasma-derived polymers and their progressive disappearance from circulation is consistent with their origin in, and canonical secretion from, the liver. To our knowledge this is the first post-transplant evaluation of the hybrid conformational profile of endogenous and donor tissue-derived AAT.

Bioscience ReportsVol. 46(12)
Royal Free London NHS Foundation Trust (GB), King Saud University (SA), Institute of Structural and Molecular Biology (GB), University College London (GB), Sapienza University of Rome (IT)
Alpha-1 Foundation, National Institute for Health and Care Research, Fondazione Telethon, University College London Hospitals NHS Foundation Trust, Medical Research Council
Good health and well-being
Protease and Inhibitor Mechanisms
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon